DiscoverCategory: All our news
All our news
We’re excited to share our upcoming presentations of two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, happening April 25-30 in Chicago, IL!
Xentech is willing to accelerate the preclinical development/validation of new anti-cancer therapeutics with a growing panel of highly predictive human tumor-based models and robust screening/profiling studies.
Looking forward to welcoming you at booth #538 or in front of the posters !
Discover
All our news
XenTech exhibits at EORTC-NCI-AACR (Barcelona, Oct. 23-25 2024)
We’ll be exhibiting at EORTC-NCI-AACR in Barcelona, stop by booth #17 !
Discover
All our news
XenTech will be attending AACR Annual Meeting in San Diego (Apr. 5-10 2024)
Olivier, Vincent and Marie cordially invite you to stop by our Booth#3645 to discuss your innovative research projects.
Discover
All our news
ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer
Discover
All our news
XenTech will attend AACR Annual Meeting in Orlando (Apr. 14-19 2023)
Philippe, Olivier and Delphine cordially invite you to stop by our Booth#618 to discuss our solid tumor PDX collection to bring your innovative research projects a step further !
Discover
All our news
XenTech will attend the World ADC London (Mar.- 13-16th)
Philippe and Olivier cordially invite you to stop by our Booth#12 to discuss our long experience in testing ADCs in our solid tumor PDX collection !
Discover
All our news
XenTech will attend the DDR inhibitors Summit 2023 (Boston, Jan. 24-26)
Our Head of R&D Oliver Déas will be delighted to discuss with you as he’ll be attending in person.
Discover
All our news
XenTech exhibits at EACR 2022 (Seville, Jun. 20-23 2022)
We’ll be exhibiting at EACR in Seville, stop by booth #50 !
Discover
Publications
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Discover
Publications
Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cellderived eXplants
CTC-derived eXplants (CDX) offer systems for mechanistic investigation of CTC metastatic potency and may provide rationale for biology-driven therapeutics.
Discover